[Cannabinoid Drugs in the Treatment of Psychiatric Disorders - Data from the German Federal Institute for Drugs and Medical Devices].

IF 1.1 4区医学 Q4 PSYCHIATRY

Psychiatrische Praxis Pub Date : 2024-09-01 Epub Date: 2024-05-15 DOI:10.1055/a-2296-1358

Felix Wülfing, Gabriele Schmidt-Wolf, Peter Cremer-Schaeffer, Kathlen Priebe, Nikola Schoofs

{"title":"[Cannabinoid Drugs in the Treatment of Psychiatric Disorders - Data from the German Federal Institute for Drugs and Medical Devices].","authors":"Felix Wülfing, Gabriele Schmidt-Wolf, Peter Cremer-Schaeffer, Kathlen Priebe, Nikola Schoofs","doi":"10.1055/a-2296-1358","DOIUrl":null,"url":null,"abstract":"Background: Since 2017 physicians in Germany can prescribe cannabis based medicines or medical cannabis with subsequent funding by the statutory health insurance system.Methods: Physicians prescribing cannabinoid drugs were legally required to take part in a survey conducted by the Federal Institute for Drugs and Medical Devices. This study analyses data from 16.809 case reports that were collected from 30.3.2017 to 31.12.2021.Results: There were 5582 cases documenting the use of cannabinoid drugs in psychiatric disorders. More than half of the prescriptions were Dronabinol. 80% of the treatments concerned somatoform disorders. Most of the treatments for other psychiatric disorders also targeted pain. Doctors reported a positive effect on symptoms in at least 75% of the cases.Discussion: Most patients with psychiatric disorders received cannabinoid drugs for pain. The evidence from randomized controlled clinical trials for the use of cannabinoid drugs in psychiatric indications is weak.","PeriodicalId":20711,"journal":{"name":"Psychiatrische Praxis","volume":" ","pages":"315-320"},"PeriodicalIF":1.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatrische Praxis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2296-1358","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Since 2017 physicians in Germany can prescribe cannabis based medicines or medical cannabis with subsequent funding by the statutory health insurance system.

Methods: Physicians prescribing cannabinoid drugs were legally required to take part in a survey conducted by the Federal Institute for Drugs and Medical Devices. This study analyses data from 16.809 case reports that were collected from 30.3.2017 to 31.12.2021.

Results: There were 5582 cases documenting the use of cannabinoid drugs in psychiatric disorders. More than half of the prescriptions were Dronabinol. 80% of the treatments concerned somatoform disorders. Most of the treatments for other psychiatric disorders also targeted pain. Doctors reported a positive effect on symptoms in at least 75% of the cases.

Discussion: Most patients with psychiatric disorders received cannabinoid drugs for pain. The evidence from randomized controlled clinical trials for the use of cannabinoid drugs in psychiatric indications is weak.

查看原文本刊更多论文

[治疗精神障碍的大麻素药物--德国联邦药物和医疗器械研究所提供的数据]。

背景：自 2017 年起，德国的医生可以开具大麻类药物或医用大麻处方，并由法定医疗保险系统提供后续资助：开具大麻类药物处方的医生必须依法参加联邦药品和医疗器械研究所进行的一项调查。本研究分析了从 2017 年 3 月 30 日至 2021 年 12 月 31 日收集的 16 809 份病例报告数据：共有 5582 个病例记录了使用大麻素药物治疗精神疾病的情况。一半以上的处方为屈大麻酚。80%的治疗涉及躯体形式障碍。对其他精神疾病的治疗大多也针对疼痛。据医生报告，至少有 75% 的病例对症状产生了积极影响：讨论：大多数精神障碍患者接受大麻素药物治疗疼痛。将大麻素药物用于精神病适应症的随机对照临床试验证据不足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psychiatrische Praxis PSYCHIATRY-

CiteScore

3.90

自引率

9.10%

发文量

103

期刊介绍： Sozialpsychiatrisch orientiert Aktuelle Originalarbeiten und fundierte Übersichten Pro-Kontra-Debatten zu Brennpunktthemen Informative Fallbeispiele Vorstellung internationaler Studien